Tous Actualités
Suivre
Abonner Epigenomics AG

Epigenomics AG

EANS-News: Epigenomics AG
Epigenomics AG to host Press Conference and Analyst Meeting for 2008 Annual Results

Berlin, Germany and Seattle, WA, U.S.A (euro adhoc) -

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
companies/press conference
March 11, 2009
- Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular
diagnostics company will hold its annual press conference and analyst
meeting on Tuesday, March 31, 2009 and present results for the fiscal
year 2008. Geert Nygaard, CEO and Oliver Schacht, CFO will give an 
overview of the operational developments as well as provide guidance 
for 2009. A conference call with Epigenomics' management will be held
later on the same day.
Press Conference and Analyst Meeting
The press conference and analyst meeting will be conducted in German 
and will be held on Tuesday, March 31, 2009 at 10 am to 12 noon CET 
at the premises of the Villa Bonn - Frankfurter Gesellschaft für 
Handel Industrie und Wirtschaft in Frankfurt am Main:
Villa Bonn
Frankfurter Gesellschaft für Handel Industrie und Wirtschaft
Siesmayerstrasse 12
60323 Frankfurt am Main
Room: Vortragsraum (OG)
Epigenomics asks interested parties to confirm their participation 
for the press conference and analyst meeting by Thursday, March 26, 
2009 by fax +49 (0)30 24 34 5- 555 or email  ir@epigenomics.com.
Conference Call
A conference call will be held on Tuesday, March 31, 2009 at 3 pm to 
4 pm CET (9 am to 10 am EST), hosted by Epigenomics' management to 
discuss 2008 financial results and outlook for 2009. The conference 
call will be conducted in English.
Dial-in number (within Germany.):  +49 868 71 790
Dial-in number (outside Germany):  +1 212 444 0297
Please dial-in at least 10 minutes prior to commencement of the 
conference call.
To follow the presentation, Epigenomics kindly ask all participants 
of the call to download the slide set from the company website prior 
to the call where it will be made available as a PDF file at 10 am 
CET (4 am EST) on the same day.
Internet link: 
http://www.epigenomics.com/en/down_loads/corporate_material/
The conference call will be recorded and also made available on the 
company website web as a MP3 file after the call.
Internet link: 
http://www.epigenomics.com/en/down_loads/corporate_material/
About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the 
development of novel products for cancer. Using DNA methylation 
biomarkers, Epigenomics' tests in development aim at diagnosing 
cancer at an early stage before symptoms occur and thereby may reduce
mortality from this dreaded disease.
Epigenomics' product pipeline contains a validated biomarker for the 
early detection of colorectal cancer in blood plasma, and further 
proprietary DNA methylation biomarkers at various stages of 
development for prostate and lung cancer detection in urine, blood 
and bronchial lavage specimens. Epigenomics' biomarker mSEPT9 for the
early detection of colorectal cancer in a simple blood sample 
demonstrated continuously highest performance in multiple clinical 
studies with in total about 3,500 individuals tested.
For development and global commercialization of in vitro diagnostic 
test products, Epigenomics pursues a non-exclusive partnering 
strategy. Strategic diagnostics industry partners include Abbott 
Molecular, Philips, Sysmex Corporation and Quest Diagnostics 
Incorporated for diagnostics test products and services, and QIAGEN 
N.V. for sample preparation solutions and research products.
Partners in the health care industry and the biomedical research 
community can access Epigenomics' portfolio of proprietary DNA 
methylation technologies and biomarkers protected by more than 150 
patent families through research products, Biomarker Services, IVD 
Development Collaborations, and Licensing. The company is 
headquartered in Berlin, Germany, and has a wholly owned subsidiary 
in Seattle, WA, U.S.A. For more information, please visit 
Epigenomics' website at www.epigenomics.com.
Epigenomics' legal disclaimer.
This communication expressly or implicitly contains certain 
forward-looking statements concerning Epigenomics AG and its 
business. Such statements involve certain known and unknown risks, 
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or 
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and 
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
end of announcement                               euro adhoc

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade

Plus de actualités: Epigenomics AG
Plus de actualités: Epigenomics AG
  • 25.02.2009 – 10:31

    Epigenomics AG Licenses Biomarker for Development of Prostate Cancer Test to Quest Diagnostics

    ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. cooperations/Molecular Diagnostics Berlin, Germany and Seattle, WA, U.S.A. (euro adhoc) - February 25, 2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, today announced that it has entered into a ...

  • 12.02.2009 – 08:01

    Epigenomics AG Successfully Places Shares at Premium in Capital Increase

    ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies/Diagnostics Berlin (euro adhoc) - 12. February 2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX; ISIN: DE000A0BVT96) successfully placed all 2,671,088 new shares that were issued in an increase of the share capital against contribution ...